The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial
Open accessAbstract
BACKGROUND: About half of the world's population lives in dengue-endemic areas. We aimed to evaluate the long-term efficacy and safety of two doses of the tetravalent dengue vaccine TAK-003 in preventing symptomatic dengue disease of any severity and due to any dengue virus (DENV) serotypes in children and adolescents. METHODS: In this ongoing double-blind, randomised, placebo-controlled trial, we enrolled healthy participants aged 4-16 years at 26 medical and research centres across eight dengue-endemic countries (Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Philippines, Sri Lanka, and Thailand). The main exclusion criteria were febrile illness (body temperature ≥38°C) at the time of randomisation, hypersensitivity or allergy to any of the vaccine components, pregnancy or breastfeeding, serious chronic or progressive disease, impaired or altered immune function, and previous receipt of a dengue vaccine. Participants were randomly assigned 2:1 (stratified by age and region) using an interactive web response system and dynamic block assignment to receive two subcutaneous doses of TAK-003 or placebo 3 months apart. Investigators, participants, and their parents or legal guardians were blinded to group assignments. Active febrile illness surveillance and RT-PCR testing of febrile illness episodes were performed for identification of virologically confirmed dengue. Efficacy outcomes were assessed in the safety analysis set (all randomly assigned participants who received ≥1 dose) and the per protocol set (all participants who had no major protocol violations), and included cumulative vaccine efficacy from first vaccination to approximately 4·5 years after the second vaccination. Serious adverse events were monitored throughout. This study is registered with ClinicalTrials.gov, NCT02747927. FINDINGS: Between Sept 7, 2016, and March 31, 2017, 20 099 participants were randomly assigned (TAK-003, n=13 401; placebo, n=6698). 20 071 participants (10 142 [50·5%] males; 9929 [49·5%] females; safety set) received TAK-003 or placebo, with 18 257 (91·0%) completing approximately 4·5 years of follow-up after the second vaccination (TAK-003, 12 177/13 380; placebo, 6080/6687). Overall, 1007 (placebo: 560; TAK-003: 447) of 27 684 febrile illnesses reported were virologically confirmed dengue, with 188 cases (placebo: 142; TAK-003: 46) requiring hospitalisation. Cumulative vaccine efficacy was 61·2% (95% CI 56·0-65·8) against virologically confirmed dengue and 84·1% (77·8-88·6) against hospitalised virologically confirmed dengue; corresponding efficacies were 53·5% (41·6-62·9) and 79·3% (63·5-88·2) in baseline seronegative participants (safety set). In an exploratory analysis, vaccine efficacy was shown against all four serotypes in baseline seropositive participants. In baseline seronegative participants, vaccine efficacy was shown against DENV-1 and DENV-2 but was not observed against DENV-3 and low incidence precluded evaluation against DENV-4. During part 3 of the trial (approximately 22-57 months after the first vaccination), serious adverse events were reported for 664 (5·0%) of 13 380 TAK-003 recipients and 396 (5·9%) of 6687 placebo recipients; 17 deaths (6 in the placebo group and 11 in the TAK-003 group) were reported, none were considered study-vaccine related. INTERPRETATION: TAK-003 demonstrated long-term efficacy and safety against all four DENV serotypes in previously exposed individuals and against DENV-1 and DENV-2 in dengue-naive individuals. FUNDING: Takeda Vaccines. TRANSLATIONS: For the Portuguese, Spanish translations and plain language summary of the abstract see Supplementary Materials section.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dengue: a continuing global threat
Guzman, M. G., Halstead, S. B., Artsob, H., Buchy, P., Farrar, J., Gubler, D. J., Hunsperger, E., Kroeger, A., Margolis, H. S., Martínez, E., et al. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2460 · Cited by 2,082
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
Sridhar, S., Luedtke, A., Langevin, E., Zhu, M., Bonaparte, M., Machabert, T., Savarino, S., Zambrano, B., Moureau, A., Khromava, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800820 · Cited by 783
Colón-González, F. J., Sewe, M. O., Tompkins, A. M., Sjödin, H., Casallas, A., Rocklöv, J., Caminade, C., & Lowe, R. (2021) · The Lancet Planetary Health · doi:10.1016/s2542-5196(21)00132-7 · Cited by 455
Bowman, L. R., Donegan, S., & McCall, P. J. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004551 · Cited by 449
Global Epidemiology of Dengue Outbreaks in 1990–2015: A Systematic Review and Meta-Analysis
Guo, C., Zhou, Z., Wen, Z., Liu, Y., Zeng, C., Xiao, D., Ou, M., Han, Y., Huang, S., Liu, D., et al. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00317 · Cited by 447
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
Biswal, S., Reynales, H., Saez-Llorens, X., Lopez, P., Borja-Tabora, C., Kosalaraksa, P., Sirivichayakul, C., Watanaveeradej, V., Rivera, L., Espinoza, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903869 · Cited by 405
Self-citationSantiago, G. A., Vergne, E., Quiles, Y., Cosme, J., Vazquez, J., Medina, J. F., Medina, F., Colón, C., Margolis, H., & Muñoz-Jordán, J. L. (2013) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002311 · Cited by 387
Soo, K.-M., Khalid, B., Ching, S.-M., & Chee, H.-Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154760 · Cited by 292
Biswal, S., Borja-Tabora, C., Martinez Vargas, L., Velásquez, H., Theresa Alera, M., Sierra, V., Johana Rodriguez-Arenales, E., Yu, D., Wickramasinghe, V. P., Duarte Moreira, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30414-1 · Cited by 263
Self-citationThree-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)
Rivera, L., Biswal, S., Sáez-Llorens, X., Reynales, H., López-Medina, E., Borja-Tabora, C., Bravo, L., Sirivichayakul, C., Kosalaraksa, P., Martinez Vargas, L., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab864 · Cited by 243
Self-citation
Metadata
- Authors
- Tricou, V., Yu, D., Reynales, H., Biswal, S., Saez-Llorens, X., Sirivichayakul, C., Lopez, P., Borja-Tabora, C., Bravo, L., Kosalaraksa, P., Vargas, L. M., Alera, M. T., Rivera, L., Watanaveeradej, V., Dietze, R., Fernando, L., Wickramasinghe, V. P., Moreira, E. D., Fernando, A. D., Gunasekera, D., Luz, K., Oliveira, A. L., Tuboi, S., Escudero, I., Hutagalung, Y., Lloyd, E., Rauscher, M., Zent, O., Folschweiller, N., LeFevre, I., Espinoza, F., & Wallace, D.
- Venue
- The Lancet Global Health
- Publisher
- Elsevier BV
- Published
- 2024-02
- Volume
- 12
- Issue
- 2
- Pages
- e257-e270
- ISSN
- 2214-109X (ISSN-L)
- OpenAlex
- W4391074691
- Cited by
- 268
- References
- 21
- FWCI
- 101.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s2214-109x(23)00522-3
- The paper
- Tricou, V., Yu, D., Reynales, H., Biswal, S., Saez-Llorens, X., Sirivichayakul, C., Lopez, P., Borja-Tabora, C., Bravo, L., Kosalaraksa, P., Vargas, L. M., Alera, M. T., Rivera, L., Watanaveeradej, V., Dietze, R., Fernando, L., Wickramasinghe, V. P., Moreira, E. D., Fernando, A. D., . . . Wallace, D. (2024). Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(23)00522-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.